Compare Dow Jones Industrial Average ETF (DIA) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs Summit Therapeutics Inc — how do they compare? Dow Jones Industrial Average ETF trades at $516.27 (market cap $45.20B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Dow Jones Industrial Average ETF is far larger — about 3.3× Summit Therapeutics Inc's market cap, and Dow Jones Industrial Average ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dow Jones Industrial Average ETF for 104 Days and Summit Therapeutics Inc for 16 Days on average.
| DIA | SMMT | |
|---|---|---|
Market Cap | $45.20B | $13.71B |
Volume | 4,095,368 | 6,173,057 |
52-Week High | $542.79 | $26.38 |
52-Week Low | $451.37 | $12.43 |
Typical Hold Time | 104 Days | 16 Days |
Sector | — | Health |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $515.82, up 0.94% with bearish technical signals from moving averages. The ETF shows neutral oscillator readings with RSI at 46.24, while recent dividend distributions provide income appeal. Support levels cluster around $507-510 with resistance at $513-516.
Market sentiment reflects cautious optimism amid economic uncertainty, with institutional focus on Fed policy and earnings resilience. Key risks include interest rate sensitivity and market volatility, though the ETF's diversified Dow Jones exposure offers defensive characteristics in turbulent markets.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
